Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial.

ABSTRACT:

Objective

The objectives of this study were to compare the efficacy, including dose response, and safety of rimegepant, an orally administered small-molecule calcitonin gene-related peptide receptor antagonist, with placebo for the acute treatment of migraine in Japan.

Background

There is a substantial unmet need for the acute treatment of migraine in Japan due to undesirable attributes of existing acute treatments.

Methods

In this Phase 2/3, double-blind, randomized trial, adults with a ≥1-year history of migraine were recruited to 50 study centers in Japan. Participants were randomly assigned to receive rimegepant 25 mg, rimegepant 75 mg, or placebo and instructed to treat a single migraine attack of moderate or severe pain intensity. The randomization was stratifie

SUBMITTER: Ikeda K 

PROVIDER: S-EPMC12638520 | biostudies-literature | 2025 Nov-Dec

REPOSITORIES: biostudies-literature